Guggenheim Capital LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 1.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 393,583 shares of the medical technology company’s stock after purchasing an additional 4,357 shares during the period. Guggenheim Capital LLC owned about 0.11% of Stryker worth $60,942,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in SYK. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Stryker by 4.5% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 172,329 shares of the medical technology company’s stock worth $24,474,000 after purchasing an additional 7,499 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Stryker by 21.2% during the third quarter. Victory Capital Management Inc. now owns 24,114 shares of the medical technology company’s stock worth $3,425,000 after purchasing an additional 4,222 shares during the last quarter. Dupont Capital Management Corp bought a new stake in shares of Stryker during the third quarter worth about $274,000. Global X MANAGEMENT CO LLC grew its holdings in shares of Stryker by 15.1% during the third quarter. Global X MANAGEMENT CO LLC now owns 6,573 shares of the medical technology company’s stock worth $933,000 after purchasing an additional 862 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Stryker by 26.8% during the third quarter. Sei Investments Co. now owns 41,104 shares of the medical technology company’s stock worth $5,838,000 after purchasing an additional 8,696 shares during the last quarter. Institutional investors own 75.71% of the company’s stock.
Several analysts have recently weighed in on SYK shares. Royal Bank of Canada restated a “buy” rating and set a $175.00 price target on shares of Stryker in a report on Tuesday, January 9th. ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. SunTrust Banks reiterated a “buy” rating and issued a $161.00 target price on shares of Stryker in a report on Friday, November 17th. Piper Jaffray Companies reiterated a “buy” rating and issued a $170.00 target price on shares of Stryker in a report on Wednesday, January 31st. Finally, Guggenheim reiterated a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $163.85.
Stryker Co. (NYSE:SYK) opened at $167.11 on Wednesday. The stock has a market capitalization of $62,898.64, a P/E ratio of 62.35, a price-to-earnings-growth ratio of 2.41 and a beta of 0.70. Stryker Co. has a twelve month low of $129.82 and a twelve month high of $170.00. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.01. The firm had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.78 EPS. sell-side analysts anticipate that Stryker Co. will post 7.12 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.13%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s payout ratio is 70.15%.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/14/guggenheim-capital-llc-grows-stake-in-stryker-co-syk.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.